Erasca (ERAS) pipeline and stated timing

Name in SEC filings: Erasca, Inc.

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
ERAS-4001	/data readout	Phase 1	second half of 2026	10-Q · Aug 11, 2026
ERAS-0015	Topline/data readout	Stage not stated	H1 2027	8-K · Aug 11, 2026

Source: ORION, orionbiotechai.com/company/ERAS, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/ERAS

Nearest upcoming stated timing: ERAS-4001 · Topline/data readout · second half of 2026

SEC sources last checked Oct 18, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

ERAS-4001

Matched

Topline/data readoutsecond half of 2026

Stage: Phase 1SEC filing · “Phase 1”

Public float: $316,400,000 · as of Jun 30, 2025 · SEC filing

We anticipate a Phase 1 monotherapy data readout from the BOREALIS-1 trial in the second half of 2026.

10-Q · Filed Aug 11, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001193125-26-344611

Alert me · Calendar: same stage and window-end month (2026-12)

ERAS-0015

Matched

Topline/data readoutH1 2027

Stage: Not stated

Public float: $316,400,000 · as of Jun 30, 2025 · SEC filing

Additional ERAS-0015 monotherapy and combination data expected in H1 2027

8-K · Filed Aug 11, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001193125-26-344584

Alert me · Calendar: same stage and window-end month (2027-06)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event	Stated period and SEC wording	Disclosure in stated period
ERAS-0015Clinical results	H1 2027 “Additional ERAS-0015 monotherapy and combination data expected in H1 2027” Filed Aug 11, 2026 · EX-99.1	Period not started The stated period has not started yet, so there is nothing to compare.
ERAS-4001Clinical results	second half of 2026 “We anticipate a Phase 1 monotherapy data readout from the BOREALIS-1 trial in the second half of 2026.” Filed Aug 11, 2026 · 10-Q	Still within period As of Oct 19, 2026
ERAS-4001Clinical results	second half of 2026 “We anticipate a Phase 1 monotherapy data readout from the BOREALIS-1 trial in the second half of 2026.” Filed May 11, 2026 · 10-Q	Still within period As of Oct 19, 2026
ERAS-4001Clinical results	second half of 2026 “ERAS-4001 is progressing through Phase 1 dose escalation, with preliminary safety, tolerability, pharmacokinetics, and early efficacy data expected in the second half of 2026.” Filed May 11, 2026 · EX-99.1	Still within period As of Oct 19, 2026
ERAS-0015Clinical results	2027 “In addition, we anticipate the initiation of monotherapy expansion cohorts and combination dose escalation cohorts as part of the AURORAS-1 trial in the second half of 2026, with associated data readouts planned for 2027.” Filed Mar 12, 2026 · 10-K	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
ERAS-4001Clinical results	second half of 2026 “We anticipate a Phase 1 monotherapy data readout from the BOREALIS-1 trial in the second half of 2026.” Filed Mar 12, 2026 · 10-K	Still within period As of Oct 19, 2026
ERAS-4001Clinical results	second half of 2026 “We anticipate a Phase 1 monotherapy data readout in the second half of 2026.” Filed Mar 12, 2026 · 10-K	Still within period As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch ERAS

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for ERAS. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See ERAS in the calendar · Review labels and methodology